Radionuclide Therapy Developers Attract Investor Attention in March China Fundraising

China's Chengdu New Radiomedicine Technology and the radiotherapy CRDMO Mitro Biotech bagged a combined $94m in their respective new financing rounds during March. Meanwhile, Beijing Varnotech Biopharm secured $83m for its vaccine candidates for the prevention of herpes zoster and respiratory syncytial virus infections.

funding — Chinese biotechs extended sizable deal-making into March • Source: Shutterstock

Chinese developers of radionuclide-based therapies snapped up sizable fundraising deals in March, backed by venture capital (VC) and private equity (PE) funds, while innovative vaccines and cell/gene therapies being developed by Chinese biotechs also continued to attract investor attention.

The most eye-catching deal involved Chengdu, Sichuan-based Chengdu New Radiomedicine Technology Co Ltd, which boasts a globalized platform for...